HC Wainwright Issues Positive Estimate for IKT Earnings

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) – Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for Inhibikase Therapeutics in a research report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.10) per share for the quarter, up from their prior estimate of ($0.12). HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.59) EPS.

IKT has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Thursday, January 22nd. LADENBURG THALM/SH SH began coverage on shares of Inhibikase Therapeutics in a research note on Wednesday, March 4th. They issued a “buy” rating and a $4.00 price target for the company. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Zacks Research raised shares of Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Finally, Wall Street Zen upgraded Inhibikase Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Four investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inhibikase Therapeutics currently has an average rating of “Buy” and an average price target of $5.50.

Inhibikase Therapeutics Stock Up 6.3%

NASDAQ:IKT opened at $1.68 on Wednesday. The company has a fifty day moving average of $1.77 and a 200-day moving average of $1.68. The firm has a market capitalization of $126.30 million, a P/E ratio of -3.50 and a beta of 0.76. Inhibikase Therapeutics has a twelve month low of $1.33 and a twelve month high of $2.37.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03.

Institutional Trading of Inhibikase Therapeutics

Several hedge funds have recently bought and sold shares of IKT. Seven Fleet Capital Management LP acquired a new position in Inhibikase Therapeutics during the fourth quarter worth $1,094,000. Virtu Financial LLC lifted its stake in shares of Inhibikase Therapeutics by 70.1% in the fourth quarter. Virtu Financial LLC now owns 22,869 shares of the company’s stock valued at $47,000 after buying an additional 9,423 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Inhibikase Therapeutics by 53.7% during the fourth quarter. ADAR1 Capital Management LLC now owns 8,063,949 shares of the company’s stock valued at $16,531,000 after buying an additional 2,816,346 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Inhibikase Therapeutics during the fourth quarter valued at about $42,000. Finally, Squadron Capital Management LLC bought a new stake in shares of Inhibikase Therapeutics during the fourth quarter worth about $8,661,000. Institutional investors and hedge funds own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.